Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Genes × Genitourinary × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Surveys and Questionnaires 43 Blood Specimen Collection 41 enzalutamide 27 radium Ra 223 dichloride 20 Biopsy 19 Docetaxel 17 apalutamide 16 Watchful Waiting 16 Radiotherapy 16 Abiraterone Acetate 16 Magnetic Resonance Spectroscopy 15 Interviews as Topic 15 darolutamide 14 Sorafenib 14 Sunitinib 13 Leuprolide 13 Gene Expression Profiling 13 Amplified Fragment Length Polymorphism Analysis 12 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 Specimen Handling 11 Observation 11 Magnetic Resonance Imaging 11 Androgen Antagonists 11 abiraterone 9 Immunohistochemistry 9 avelumab 8 Radiosurgery 8 Data Collection 8 cabozantinib 7 Polymerase Chain Reaction 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03152448 2022-06-13

P-PROVE

Myriad Genetic Laboratories, Inc.

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡